Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

National Research (NRC) Cash & Equivalents (2016 - 2025)

National Research's Cash & Equivalents history spans 16 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 1.45% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, down 1.45%, while the annual FY2025 figure was $4.1 million, 1.45% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $4.1 million at National Research, up from $2.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $54.4 million in Q4 2021 and bottomed at $485000.0 in Q2 2024.
  • The 5-year median for Cash & Equivalents is $14.6 million (2023), against an average of $20.7 million.
  • The largest annual shift saw Cash & Equivalents tumbled 97.84% in 2024 before it skyrocketed 987.42% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $54.4 million in 2021, then plummeted by 53.96% to $25.0 million in 2022, then tumbled by 73.42% to $6.7 million in 2023, then tumbled by 36.87% to $4.2 million in 2024, then fell by 1.45% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRC's Cash & Equivalents are $4.1 million (Q4 2025), $2.2 million (Q3 2025), and $5.3 million (Q2 2025).